Last reviewed · How we verify
Losartan Tablets & QingReMoShen Granule
Losartan Tablets & QingReMoShen Granule is a Small molecule drug developed by wanglin. It is currently in Phase 1 development.
At a glance
| Generic name | Losartan Tablets & QingReMoShen Granule |
|---|---|
| Sponsor | wanglin |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Losartan Tablets & QingReMoShen Granule CI brief — competitive landscape report
- Losartan Tablets & QingReMoShen Granule updates RSS · CI watch RSS
- wanglin portfolio CI
Frequently asked questions about Losartan Tablets & QingReMoShen Granule
What is Losartan Tablets & QingReMoShen Granule?
Losartan Tablets & QingReMoShen Granule is a Small molecule drug developed by wanglin.
Who makes Losartan Tablets & QingReMoShen Granule?
Losartan Tablets & QingReMoShen Granule is developed by wanglin (see full wanglin pipeline at /company/wanglin).
What development phase is Losartan Tablets & QingReMoShen Granule in?
Losartan Tablets & QingReMoShen Granule is in Phase 1.